COX-2 Inhibition and Inhibition of Cytosolic Phospholipase A2 Increase CD36 Expression and Foam Cell Formation in THP-1 Cells

Disruption of Cholesterol Efflux by Coxib Medications and Inflammatory Processes

(2016) Allison B. Reiss et al.   JOURNAL OF INVESTIGATIVE MEDICINE

Leukotrienes and Atherosclerosis

(2010) Graziano Riccioni et al.   CURRENT DRUG TARGETS

Inhibition of CD36-Dependent Phagocytosis by Prostaglandin E2 Contributes to the Development of Endometriosis

(2009) Pei-Chin Chuang et al.   AMERICAN JOURNAL OF PATHOLOGY

The LDL Receptor

(2009) Joseph L. Goldstein et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

CD36-mediated cholesterol efflux is associated with PPARγ activation via a MAPK-dependent COX-2 pathway in macrophages

(2009) Kim Bujold et al.   CARDIOVASCULAR RESEARCH

Heart Disease and Stroke Statistics—2009 Update

(2009) et al.   CIRCULATION

Inflammation, atherosclerosis, and arterial thrombosis: Role of the scavenger receptor CD36

(2009) R. L. SILVERSTEIN   CLEVELAND CLINIC JOURNAL OF MEDICINE

A BRIEF COMMUNICATION

(2009) Allison B. Reiss et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism

(2009) H. A. Elrod et al.   MOLECULAR CANCER THERAPEUTICS

Genetic and pharmacological inhibition of the 5-lipoxygenase/leukotriene pathway in atherosclerotic lesion development in ApoE deficient mice

(2008) Richard Yang Cao et al.   ATHEROSCLEROSIS

Cyclooxygenase-2 Inhibitors, Nonsteroidal Anti-inflammatory Drugs, and Cardiovascular Risk

(2008) Orly Vardeny et al.   CARDIOLOGY CLINICS

The macrophage scavenger receptor at 30 years of age: current knowledge and future challenges: TABLE 1.

(2008) David R. Greaves et al.   JOURNAL OF LIPID RESEARCH